Evidence map›Paper›PMID 41725626›Full record

ArticleTherapeutic advances in drug safety2026

The magnitude of drug-related problems, typology, and predictors among patients admitted to the pediatric intensive care unit: impact of pharmacist-led interventions in Northwest Ethiopia.

Abel Temeche Kassaw, Getachew Yitayew Tarekegn, Tigabu Eskeziya Zerihun, Abaynesh Fentahun Bekalu, Samuel Agegnew Wondm, Tilaye Arega Moges, Woretaw Sisay Zewdu, Fasil Bayafers Tamene, Desalegn Addis Mussie, Samuel Berihun Dagnew

Abstract read
In one paragraph

Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Drug-related problems and their predictors in pediatric community-acquired infections: the role of pharmacist-led interventions in Pakistan.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abel Temeche KassawDepartment of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, P.O. Box 272, Debre Tabor, Ethiopia.ORCID https://orcid.org/0009-0008-3431-8187
Getachew Yitayew TarekegnDepartment of Clinical Pharmacy, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia.ORCID https://orcid.org/0000-0002-8678-6723
Tigabu Eskeziya ZerihunDepartment of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.ORCID https://orcid.org/0009-0005-2616-397X
Abaynesh Fentahun BekaluDepartment of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Samuel Agegnew WondmDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Tilaye Arega MogesDepartment of Clinical Pharmacy, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia.
Woretaw Sisay ZewduDepartment of Pharmacology and Toxicology, Pharmacy Education and Clinical Services Directorate, Debre Tabor University, Debre Tabor, Ethiopia.
Fasil Bayafers TameneDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Desalegn Addis MussieDepartment of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Samuel Berihun DagnewDepartment of Clinical Pharmacy, College of Health Science, Debre Tabor University, Debre Tabor, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Drug-related problems (DRPs) are a significant concern in hospitalized patients. In Ethiopia, DRPs occur at a rate of 9.2 per 100 admissions and 9.4 per 1,000 patient days; however, pediatric-specific data are limited. Objective: This study assessed the magnitude, types, and predictors of DRPs and evaluated the acceptability of pharmacist-led interventions in pediatric intensive care units (PICUs) in Northwest Ethiopia. Design: A multicenter prospective interventional study. Methods: All pediatric patients admitted to the PICU during the study period were consecutively enrolled. The study was conducted from January 1, 2025 to March 31, 2025 across four specialized hospitals, resulting in a total of 394 participants. DRPs were identified through medical record reviews, caregiver interviews, and direct bedside assessment by a clinical pharmacist. Each DRP was classified according to the Pharmaceutical Care Network Europe (PCNE) classification system version 8.01. Binary logistic regression was performed to identify independent predictors of DRPs. Results: Of the patients, 251 (63.7%) experienced at least one DRP, with 522 DRPs identified (mean 1.3 ± 0.8 per patient). The dominant domains were treatment effectiveness (54.6%) and treatment safety (30.3%), and 97.7% were deemed preventable. Drug and dose selection were the main causes (46.0% and 43.8%, respectively). Independent predictors included age 29 days-1 year (AOR = 2.2, 95% CI: 1.0-4.8), polypharmacy (⩾5 medications; AOR = 1.7, 95% CI: 1.0-2.8), multiple prescribers (AOR = 1.8, 95% CI: 1.1-2.9), prolonged ICU stay (⩾10 days; AOR = 2.4, 95%CI: 1.2-4.7), circulatory system disease (AOR = 3.5, 95% CI: 1.4-9.0), the use of anti-infectives (AOR = 5.0, 95% CI: 2.0-13.7), and antiepileptics medications (AOR = 2.1, 95% CI: 1.0-4.3) were independent predictors of DRPs. Conclusion: DRPs were common in PICU but predominantly preventable. Despite a modest mean number of DRPs per patient, the type and causes identified indicate opportunities for optimizing medication use. Younger age, polypharmacy, multiple prescribers, prolonged PICU stays, circulatory system disease, and specific drug classes were independent predictors. The high acceptance and effectiveness of pharmacist-led interventions underscore their crucial role in improving medication safety and optimizing pharmacotherapy in resource-limited intensive care settings.

Indexed as

clinical pharmacist interventionsdrug-related problems (DRPs)Ethiopiapediatrics intensive care unit (PICU)Pharmaceutical Care Network of Europe classification (PCNE)

Identifiers

PMID41725626
PMCPMC12923928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.